Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Li, Rui ^a   You, Shuo ^a   Hu, Zhongliang ^a   Chen, Zhuo G ^a   Sica, Gabriel L ^a   Khuri, Fadlo R ^a   Curran, Walter J ^a   Shin, Dong M ^a   Deng, Xingming ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NICLOSAMIDE; PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN PTPMEG2; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; NICLOSAMIDE; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84883409071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074670     Document Type: Article

References (40)

1. Sano D, Myers JN, (2009) Xenograft models of head and neck cancers. Head Neck Oncol. 1: 32.
2. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
3. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, et al. (2010) Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2571-2579. doi:10.1158/1078-0432.CCR-10-0333. PubMed: 20388852.
4. Forastiere A, Koch W, Trotti A, Sidransky D, (2001) Head and neck cancer. N Engl J Med 345: 1890-1900. doi:10.1056/NEJMra001375. PubMed: 11756581.
5. Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR, (2012) Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther 13: 935-945. doi:10.4161/cbt.20846. PubMed: 22785204.
6. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, et al. (2009) gp130-mediated. Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102.
7. Lee H, Deng J, Kujawski M, Yang C, Liu Y, et al. (2010) STAT3-induced S1PR1 expression is crucial for persistent. Stat 3 activation in tumors. Nat Med 16: 1421-1428.
8. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, et al. (2011). tat 3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
9. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. (2007) Mutations in the EGFR kinase domain mediate. Stat 3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856.
10. Haura EB, Zheng Z, Song L, Cantor A, Bepler G, (2005) Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294. doi:10.1158/1078-0432.CCR-05-0827. PubMed: 16322287.
11. Lai SY, Johnson FM, (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Update 13: 67-78. doi:10.1016/j.drup.2010.04.001. PubMed: 20471303.
12. Bharti AC, Donato N, Aggarwal BB, (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible. Stat 3 phosphorylation in human multiple myeloma cells. J Immunol 171: 3863-3871.
13. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, et al. (2005) New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 4: 1131-1133. doi:10.4161/cc.4.9.1985. PubMed: 16082218.
14. Yu H, Jove R, (2004) The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 4: 97-105. doi:10.1038/nrc1275. PubMed: 14964307.
15. Su F, Ren F, Rong Y, Wang Y, Geng Y, et al. (2012) Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res 14: R38. doi:10.1186/bcr3134. PubMed: 22394684.
16. Xi S, Gooding WE, Grandis JR, (2005) In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24: 970-979. doi:10.1038/sj.onc.1208316. PubMed: 15592503.
17. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, et al. (2008) Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 73: 1632-1642. doi:10.1124/mol.107.044636. PubMed: 18326051.
18. Ren XM, Duan L, He QA, Zhang Z, Zhou Y, et al. (2010) Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett 1: 454-459. doi:10.1021/ml100146z.
19. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, et al. (2004) Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 5930-5939. doi:10.1158/1078-0432.CCR-03-0677. PubMed: 15355926.
20. Ito T, Deng X, Carr B, May WS, (1997) Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 272: 11671-11673. doi:10.1074/jbc.272.18.11671. PubMed: 9115213.
21. Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou P, (2012) Microtubules regulate hypoxia-inducible factor-1alpha protein trafficking and activity: implications for taxane therapy. J Biol Chem 287: 11859-11869. doi:10.1074/jbc.M112.345587. PubMed: 22367210.
22. Boisvert H, Duncan MJ, (2010) Translocation of Porphyromonas gingivalis gingipain adhesin peptide A44 to host mitochondria prevents apoptosis. Infect Immun 78: 3616-3624. doi:10.1128/IAI.00187-10. PubMed: 20547744.
23. Huang S, Okumura K, Sinicrope FA, (2009) BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 15: 150-159. doi:10.1158/1078-0432.CCR-08-1575. PubMed: 19118042.
24. Liu Y, Sun SY, Owonikoko TK, Sica GL, Curran WJ, et al. (2012) Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Mol Cancer Ther 11: 45-56. doi:10.1158/1535-7163.MCT-11-0578. PubMed: 22057915.
25. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681. doi:10.1038/nature03579. PubMed: 15902208.
26. Liu AW, Cai J, Zhao XL, Jiang TH, He TF, et al. (2011) ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 17: 710-720. doi:10.1158/1078-0432.CCR-10-0331. PubMed: 21196414.
27. Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, et al. (2007) Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2: 1152-1165. doi:10.1038/nprot.2007.107. PubMed: 17546006.
28. Xu J, Müller S, Nannapaneni S, Pan L, Wang Y, et al. (2012) Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer, 48: 1682-91. PubMed: 22341992.
29. Huang DH, Su L, Peng XH, Zhang H, Khuri FR, et al. (2009) Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. Nanotechnology 20: 225102. doi:10.1088/0957-4484/20/22/225102. PubMed: 19433879.
30. Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, et al. (2008) Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 7: 1952-1958. doi:10.4161/cbt.7.12.6944. PubMed: 18981735.
31. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446. doi:10.1158/1538-7445.AM10-440. PubMed: 20068163.
32. Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, et al. (2011) MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res 71: 4494-4505. doi:10.1158/1538-7445.AM2011-4494. PubMed: 21555370.
33. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115. doi:10.1016/S1074-7613(00)80011-4. PubMed: 10023775.
34. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao YX, Pestell RG, et al. (1999). tat 3 as an oncogene. Cell 98: 295.
35. Alas S, Bonavida B, (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137-5144. PubMed: 11431352.
36. Huang DH, Peng XH, Su L, Wang DS, Khuri FR, et al. (2010) Comparison and Optimization of Multiplexed Quantum Dot-Based Immunohistofluorescence. Nano Research 3: 61-68. doi:10.1007/s12274-010-1009-1.
37. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, et al. (2012) Targeting. Stat 3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 18: 4986-4996.
38. Nie S, Xing Y, Kim GJ, Simons JW, (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng 9: 257-288. doi:10.1146/annurev.bioeng.9.060906.152025. PubMed: 17439359.
39. Bruchez M Jr., Moronne M, Gin P, Weiss S, Alivisatos AP, (1998) Semiconductor nanocrystals as fluorescent biological labels. Science 281: 2013-2016. doi:10.1126/science.281.5385.2013. PubMed: 9748157.
40. Ferrari M, (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5: 161-171. doi:10.1038/nrc1566. PubMed: 15738981.